• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾功能对普瑞巴林治疗周围神经病理性疼痛患者剂量滴定和依从性关系的影响:一项全国性电子病历数据库研究。

Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study.

机构信息

Department of Patient Safety Unit/Anesthesia, Kyoto University Hospital, Kyoto, Japan.

Medical Affairs Division, Daiichi Sankyo Co., Ltd, Tokyo, Japan.

出版信息

Expert Opin Pharmacother. 2023 Feb;24(2):267-282. doi: 10.1080/14656566.2022.2155048. Epub 2022 Dec 15.

DOI:10.1080/14656566.2022.2155048
PMID:36503333
Abstract

BACKGROUND

Mirogabalin has been attracting attention for treating peripheral neuropathic pain. The package insert recommends that mirogabalin should be titrated depending on renal function. Here, we investigated the relationship between dose titration patterns and adherence, and persistence of mirogabalin treatment.

RESEARCH DESIGN AND METHODS

Peripheral neuropathic pain patients who initiated mirogabalin between March 2020 and May 2021 were identified using an electronic medical record database. The dose titration pattern was described according to degrees of renal function. Regression analyses were performed to compare adherence and persistence between the patients with and without titration.

RESULTS

Of the 4,138 identified patients, 1,696 (41.0%) titrated the dose within 45 days and were more adherent than those without titration (Adjusted odds ratio: 1.75, 95% CI 1.21, 2.54). Of the total 952 patients with renal function parameters, 229 (24.1%) titrated to the effective dose within 45 days and were less likely to discontinue than those without titration (Adjusted hazard ratio: 0.57, 95% CI 0.40, 0.81).

CONCLUSION

Mirogabalin dose titration was associated with better adherence and persistence. It is important for mirogabalin treatment to determine the initial prescription dose based on renal function and subsequent dose titration according to the package insert.

TRIAL REGISTRATION

UMIN000047313.

摘要

背景

米罗 gabalin 因其治疗周围神经性疼痛而受到关注。说明书建议根据肾功能调整米罗 gabalin 的剂量。在此,我们研究了剂量调整模式与米罗 gabalin 治疗的依从性和持续性之间的关系。

研究设计和方法

使用电子病历数据库,确定了 2020 年 3 月至 2021 年 5 月期间开始使用米罗 gabalin 的周围神经性疼痛患者。根据肾功能程度描述剂量调整模式。回归分析比较了剂量调整和未调整患者的依从性和持续性。

结果

在确定的 4138 名患者中,有 1696 名(41.0%)在 45 天内调整了剂量,比未调整剂量的患者更具依从性(调整后的优势比:1.75,95%可信区间 1.21,2.54)。在有肾功能参数的 952 名患者中,有 229 名(24.1%)在 45 天内调整至有效剂量,比未调整剂量的患者更不容易停药(调整后的危险比:0.57,95%可信区间 0.40,0.81)。

结论

米罗 gabalin 剂量调整与更好的依从性和持续性相关。根据肾功能确定初始处方剂量,并根据说明书进行后续剂量调整,对于米罗 gabalin 治疗非常重要。

试验注册

UMIN000047313。

相似文献

1
Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study.肾功能对普瑞巴林治疗周围神经病理性疼痛患者剂量滴定和依从性关系的影响:一项全国性电子病历数据库研究。
Expert Opin Pharmacother. 2023 Feb;24(2):267-282. doi: 10.1080/14656566.2022.2155048. Epub 2022 Dec 15.
2
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.米拉贝隆治疗糖尿病周围神经性疼痛的随机、双盲、安慰剂对照 III 期亚洲患者研究。
J Diabetes Investig. 2019 Sep;10(5):1299-1306. doi: 10.1111/jdi.13013. Epub 2019 Feb 28.
3
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.米罗加巴林治疗周围神经性疼痛患者的短期疗效:一项回顾性研究。
J Orthop Surg Res. 2020 May 26;15(1):191. doi: 10.1186/s13018-020-01709-3.
4
Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.米罗加巴林用于治疗外周神经性疼痛的安全性和有效性:两项关键III期研究的汇总分析
Clin Ther. 2021 May;43(5):822-835.e16. doi: 10.1016/j.clinthera.2021.03.015. Epub 2021 May 29.
5
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.米拉加巴林(DS-5565)治疗糖尿病性周围神经病理性疼痛患者的平均每日疼痛评分、头晕和嗜睡的暴露-反应模型。
J Clin Pharmacol. 2016 Jan;56(1):67-77. doi: 10.1002/jcph.567. Epub 2015 Aug 20.
6
Predictors of the usefulness of mirogabalin for neuropathic pain: a single-institution retrospective study.米罗加巴林治疗神经病理性疼痛的有效性预测因素:单机构回顾性研究。
Pharmazie. 2020 Nov 1;75(11):602-605. doi: 10.1691/ph.2020.0741.
7
A large-scale database study for the prescription status of a new voltage-gated Ca channel αδ ligand, mirogabalin, in Japan.一项关于新型电压门控钙通道 αδ 配体米罗加巴林在日本处方状况的大规模数据库研究。
Expert Opin Pharmacother. 2022 Feb;23(2):273-283. doi: 10.1080/14656566.2021.2007239. Epub 2021 Dec 20.
8
Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.米拉巴仑治疗亚洲糖尿病周围神经性疼痛患者的长期安全性和疗效。
J Diabetes Investig. 2020 May;11(3):693-698. doi: 10.1111/jdi.13178. Epub 2019 Dec 25.
9
Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study.附加米罗加巴林治疗胸外科术后周围神经性疼痛的疗效和安全性:多中心、随机、开放标签 ADMIT-NeP 研究。
BMC Cancer. 2024 Jan 15;24(1):80. doi: 10.1186/s12885-023-11708-2.
10
Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.米拉巴仑(DS-5565)治疗糖尿病周围神经病理性疼痛患者报告的疼痛和睡眠干扰的疗效:一项概念验证性 II 期研究的次要结局。
Pain Med. 2017 Nov 1;18(11):2198-2207. doi: 10.1093/pm/pnw342.

引用本文的文献

1
Safety and Efficacy of Mirogabalin in Lumbar Spinal Stenosis Patients with Peripheral Neuropathic Pain on NSAIDs: Post Hoc Analysis of the MiroTAS Study.米罗加巴林在使用非甾体抗炎药的腰椎管狭窄伴周围神经性疼痛患者中的安全性和有效性:米罗TAS研究的事后分析
Pain Ther. 2025 May 7. doi: 10.1007/s40122-025-00732-8.
2
Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.晚期癌症和重病疼痛的新型药物治疗:聚焦神经性疼痛和化疗引起的周围神经病变
Palliat Care Soc Pract. 2024 Jul 31;18:26323524241266603. doi: 10.1177/26323524241266603. eCollection 2024.